School of Medicine
Showing 201-250 of 623 Results
-
Harcharan Gill
Kathryn Simmons Stamey Professor, Emeritus
Current Research and Scholarly InterestsBenign Prostatic Hyperplasia- Evaluation and development of new minimally invasive techniques
Endourology: developing, designing and evaluating new instruments
Bladder cancer: outcomes of treatment
BPH: cryotherapy and HIFU -
Jeffrey S. Glenn, M.D., Ph.D.
Joseph D. Grant Professor and Professor of Microbiology and Immunology
Current Research and Scholarly InterestsDr. Glenn's primary interest is in molecular virology, with a strong emphasis on translating this knowledge into novel antiviral therapies. Other interests include exploitation of hepatic stem cells, engineered human liver tissues, liver cancer, and new biodefense antiviral strategies.
-
Gary Glover
Professor of Radiology (Radiological Sciences Lab) and, by courtesy, of Psychology and of Electrical Engineering
Current Research and Scholarly InterestsMy present research is devoted to the advancement of functional magnetic resonance imaging sciences for applications in basic understanding of the brain in health and disease. We collaborate closely with departmental clinicians and with others in the school of medicine, humanities, and the engineering sciences.
-
Jeremy Goldhaber-Fiebert
Professor of Health Policy
BioJeremy Goldhaber-Fiebert, PhD, is a Professor of Health Policy and a Core Faculty Member in the Centers for Health Policy and Primary Care and Outcomes Research. His research focuses on complex policy decisions surrounding the prevention and management of increasingly common, chronic diseases and the life course impact of exposure to their risk factors. In the context of both developing and developed countries including the US, India, China, and South Africa, he has examined chronic conditions including type 2 diabetes and cardiovascular diseases, human papillomavirus and cervical cancer, tuberculosis, and hepatitis C and on risk factors including smoking, physical activity, obesity, malnutrition, and other diseases themselves. He combines simulation modeling methods and cost-effectiveness analyses with econometric approaches and behavioral economic studies to address these issues. Dr. Goldhaber-Fiebert graduated magna cum laude from Harvard College in 1997, with an A.B. in the History and Literature of America. After working as a software engineer and consultant, he conducted a year-long public health research program in Costa Rica with his wife in 2001. Winner of the Lee B. Lusted Prize for Outstanding Student Research from the Society for Medical Decision Making in 2006 and in 2008, he completed his PhD in Health Policy concentrating in Decision Science at Harvard University in 2008. He was elected as a Trustee of the Society for Medical Decision Making in 2011 and Secretary/Treasurer in 2021.
Past and current research topics:
- Type 2 diabetes and cardiovascular risk factors: Randomized and observational studies in Costa Rica examining the impact of community-based lifestyle interventions and the relationship of gender, risk factors, and care utilization.
-Cervical cancer: Model-based cost-effectiveness analyses and costing methods studies that examine policy issues relating to cervical cancer screening and human papillomavirus vaccination in countries including the United States, Brazil, India, Kenya, Peru, South Africa, Tanzania, and Thailand.
- Measles, haemophilus influenzae type b, and other childhood infectious diseases: Longitudinal regression analyses of country-level data from middle and upper income countries that examine the link between vaccination, sustained reductions in mortality, and evidence of herd immunity.
- Patient adherence: Studies in both developing and developed countries of the costs and effectiveness of measures to increase successful adherence. Adherence to cervical cancer screening as well as to disease management programs targeting depression and obesity is examined from both a decision-analytic and a behavioral economics perspective.
- Simulation modeling methods: Research examining model calibration and validation, the appropriate representation of uncertainty in projected outcomes, the use of models to examine plausible counterfactuals at the biological and epidemiological level, and the reflection of population and spatial heterogeneity. -
Zinaida Good, Ph.D.
Assistant Professor of Medicine (Immunology and Rheumatology)
Current Research and Scholarly InterestsOur laboratory integrates cutting-edge synthetic biology, immunology, and machine learning to engineer T cell therapies for cancer and autoimmune diseases. We have 3 research areas:
- Analysis of clinical single-cell and spatial transcriptomics datasets from T cell therapy trials to identify mechanisms of resistance
- Building AI systems to generate T cell designs predicted to improve patient outcomes
- Genetic screens of novel T cell designs in models that mimic key mechanisms of resistance -
Miriam B. Goodman
Mrs. George A. Winzer Professor of Cell Biology
Current Research and Scholarly InterestsWe study the molecular events that give rise to the sensation of touch and chemical stressors that compromise touch sensation in C. elegans. To do this, we use a combination of quantitative behavioral analysis, genetics, in vivo electrophysiology, and heterologous expression of ion channels. We collaborate with physicists and other physiologist to expand our experimental research.
-
Steven Goodman
Professor of Epidemiology and Population Health, of Medicine (Primary Care and Population Health) and, by courtesy, of Health Policy
Current Research and Scholarly InterestsI study issues relating to the representation and measurement of evidence in medical research and determinants of the reliability of biomedical research findings. I also do work in evidence synthesis, comparative effectiveness research, and the ethics of clinical research.
-
Jason Gotlib
Professor of Medicine (Hematology)
Current Research and Scholarly InterestsMy research interests include phase I/II clinical trial evaluation of novel therapies for the following diseases:
--Myelodysplastic syndromes (MDS)
--Chronic myelogenous leukemia (CML)
--Acute myelogenous leukemia (AML)
--Myeloproliferative disorders (MPDs) including:
Hypereosinophilic syndrome
Systemic mastocytosis
BCR-ABL-negative MPDs -
Or Gozani
Dr. Morris Herzstein Professor
Current Research and Scholarly InterestsWe study the molecular mechanisms by which chromatin-signaling networks effect nuclear and epigenetic programs, and how dysregulation of these pathways leads to disease. Our work centers on the biology of lysine methylation, a principal chromatin-regulatory mechanism that directs epigenetic processes. We study how lysine methylation events are generated, sensed, and transduced, and how these chemical marks integrate with other nuclear signaling systems to govern diverse cellular functions.
-
Dita Gratzinger
Professor of Pathology
Current Research and Scholarly InterestsI have research interests in the interaction of normal and neoplastic hematolymphoid cells with the bone marrow. lymph node and spleen microenvironment and the interactions of these compartments with immune perturbation and dysregulation.
-
Edward Graves
Professor of Radiation Oncology (Radiation Physics), and by courtesy, of Radiology
Current Research and Scholarly InterestsApplications of molecular imaging in radiation therapy, small animal image-guided conformal radiotherapy, immune responses to radiation, immunotherapy and radiotherapy combinations, image processing and analysis.
-
Nathanael S. Gray
Krishnan-Shah Family Professor
BioNathanael Gray is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). His research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance.
Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. During his six year stay at GNF, Dr. Gray became the director of biological chemistry where he supervised a group of over fifty researchers integrating chemical, biological and pharmacological approaches towards the development of new experimental drugs. Some of the notable accomplishments of Dr. Gray’s team at GNF include: discovery of the first allosteric inhibitors of wild-type and mutant forms of BCR-ABL which resulted in clinical development of ABL001; discovery of the first selective inhibitors of the Anaplastic Lymphoma Kinase (ALK), an achievement that led to the development of now FDA-approved drugs such as ceritinib (LDK378) for the treatment of EML4-ALK expressing non-small cell lung cancer (NSCLC); and discovery that sphingosine-1-phosphate receptor-1 (S1P1) is the pharmacologically relevant target of the immunosuppressant drug Fingomilod (FTY720) followed by the development of Siponimod (BAF312), which is currently used for the treatment of multiple sclerosis.
In 2006, Dr. Gray returned to academia as a faculty member at the Dana Farber Cancer Institute and Harvard Medical School in Boston. There, he has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Dr. Gray’s team developed covalent inhibitors of the T790M mutant of EGFR inspired the development of Osimertinib (AZD9291), now FDA approved for treatment of patients with relapsed lung cancer due to resistance to first generation EGFR inhibitors. Dr. Gray has also developed structure-based, generalized approaches for designing drugs to overcome one of the most common mechanisms of resistance observed against most kinase inhibitor drugs, mutation of the so-called "gatekeeper" residue, which has been observed in resistance to drugs targeting BCR-ABL, c-KIT and PDGFR.
In 2021, Dr. Gray joined Stanford University where he has joined the Stanford Cancer Institute, Chem-H and the Innovative Medicines Accelerator (IMA) to spur the development of prototype drugs.
These contributions have been recognized through numerous awards including the National Science Foundation’s Career award in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011, and the Nancy Lurie Marks endowed professorship in 2015 and the Paul Marks Prize in 2019, and the Hope Funds for Cancer Research in 2023. -
Henry T. (Hank) Greely
Deane F. and Kate Edelman Johnson Professor of Law and, Professor, by courtesy, of Genetics
Current Research and Scholarly InterestsSince 1992 my work has concentrated on ethical, legal, and social issues in the biosciences. I am particularly active on issues arising from neuroscience, human genetics, and stem cell research, with cross-cutting interests in human research protections, human biological enhancement, and the future of human reproduction.
-
Harry B Greenberg
Joseph D. Grant Professor in the School of Medicine, Emeritus
Current Research and Scholarly InterestsMolecular mechanisms of pathogenesis; determinants of protective immunity; host range and tissue tropism in liver and GI tract pathogenic viruses and studies of vaccines in people.
-
Peter Greenberg
Professor of Medicine (Hematology), Emeritus
Current Research and Scholarly InterestsDr Greenberg's clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. These studies are particularly based on his prior laboratory investigations of gene expression and hematopoietic regulation in MDS patients. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the mutation-based prognostic risk system, the IPSS-Molecular (IPSS-M). This project uses such findings to more specifically characterize and treat MDS patients. He is Chair of the NCCN Practice Guidelines Panel for MDS.
-
William Greenleaf
Professor of Genetics
Current Research and Scholarly InterestsOur lab focuses on developing methods to probe both the structure and function of molecules encoded by the genome, as well as the physical compaction and folding of the genome itself. Our efforts are split between building new tools to leverage the power of high-throughput sequencing technologies and cutting-edge optical microscopies, and bringing these technologies to bear against basic biological questions by linking DNA sequence, structure, and function.
-
Xuejun Gu
Associate Professor of Radiation Oncology (Medical Physics)
Current Research and Scholarly InterestsArtificial intelligence in medicine
Medical imaging and image anlysis
Treatment planning and clinical decision-making
FLASH radiobiology study ; -
James Hallenbeck, MD
Associate Professor of Medicine (Primary Care and Population Health) at the Palo Alto Veterans Affairs Health Care System, Emeritus
Current Research and Scholarly InterestsResearch in hospice and palliative care with emphases on physician education, cultural aspects of end-of-life care, and healthcare system issues.
-
Bonnie Halpern-Felsher
Marron and Mary Elizabeth Kendrick Professor of Pediatrics and Professor, by courtesy, of Epidemiology and Population Health and of Psychiatry and Behavioral Sciences (Child and Adolescent Psychiatry)
Current Research and Scholarly InterestsResearch focuses on developmental, cognitive and psychosocial factors involved in adolescents’ and young adults’ health-related decision-making, perceptions of risk and vulnerability, health communication and risk behavior. My research has focused on understanding and reducing health risk behaviors such as tobacco use, alcohol and marijuana use, risky driving, and risky sexual behavior.
-
Summer Han
Associate Professor (Research) of Neurosurgery, of Medicine (Biomedical Informatics) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsMy current research focuses on understanding the genetic and environmental etiology of complex disease and developing and evaluating efficient screening strategies based on etiological understanding. The areas of my research interests include statistical genetics, molecular epidemiology, cancer screening, health policy modeling, and risk prediction modeling. I have developed various statistical methods to analyze high-dimensional data to identify genetic and environmental risk factors and their interactions for complex disease.
-
Philip C. Hanawalt
Dr. Morris Herzstein Professor in Biology, Emeritus
Current Research and Scholarly InterestsMy current interest includes two principal areas:
1. The molecular basis for diseases in which the pathway of transcription-coupled DNA repair is defective, including Cockyne syndrome (CS) and UV-sensitive syndrome (UVSS). Patients are severely sensitive to sunlight but get no cancers. See Hanawalt & Spivak, 2008, for review.
2. Transcription arrest by guanine-rich DNA sequences and non-canonical secondary structures. Transcription collisions with replication forks. -
Steven Hancock, MD
Professor of Radiation Oncology (Radiation Therapy), Emeritus
Current Research and Scholarly InterestsOutcomes of radiation treatment for prostate cancer. Clinical research interests in the late effects of radiation on normal tissues and chemical modification of radiation injury. Hodgkins's disease and late effects of radiation and combined modality therapy. Radiation sensitizers. Hypoxic cell cytotoxins. Esophageal cancers.
General adult and pediatric radiation therapy. -
Pehr Harbury
Associate Professor of Biochemistry
Current Research and Scholarly InterestsScientific breakthroughs often come on the heels of technological advances; advances that expose hidden truths of nature, and provide tools for engineering the world around us. Examples include the telescope (heliocentrism), the Michelson interferometer (relativity) and recombinant DNA (molecular evolution). Our lab explores innovative experimental approaches to problems in molecular biochemistry, focusing on technologies with the potential for broad impact.
-
Brian A. Hargreaves
Professor of Radiology (Radiological Sciences Laboratory) and, by courtesy, of Electrical Engineering and of Bioengineering
Current Research and Scholarly InterestsI am interested in magnetic resonance imaging (MRI) applications and augmented reality applications in medicine. These include abdominal, breast and musculoskeletal imaging, which require development of faster, quantitative, and more efficient MRI methods that provide improved diagnostic contrast compared with current methods. My work includes novel excitation schemes, efficient imaging methods and reconstruction tools and augmented reality in medicine.
-
William Haskell
Professor (Research) of Medicine, Emeritus
Current Research and Scholarly InterestsMy major research interests and activities over the next several years will focus on the development and evaluation of the objective measurement of physical activity in free-living populations using a variety of sensing devices and mobile phones for data collection and processing. Also, I will continue to direct the Stanford Heart Network with the major mission being to assist community-based CVD prevention/treatment programs implement more effective heart attack and stroke prevention programs.
-
Trevor Hastie
John A. Overdeck Professor, Professor of Statistics and of Biomedical Data Sciences, Emeritus
Current Research and Scholarly InterestsFlexible statistical modeling for prediction and representation of data arising in biology, medicine, science or industry. Statistical and machine learning tools have gained importance over the years. Part of Hastie's work has been to bridge the gap between traditional statistical methodology and the achievements made in machine learning.
-
Melanie Hayden Gephart
Professor of Neurosurgery and, by courtesy, of Neurology and Neurological Sciences
BioI am a brain tumor neurosurgeon, treating patients with malignant and benign tumors, including gliomas, brain metastases, meningiomas, and schwannomas. I direct the Stanford Brain Tumor Center and the Stanford Brain Metastasis Consortium, collaborative unions of physicians and scientists looking to improve our understanding and treatment of brain tumors. My laboratory seeks greater understanding of the mechanisms driving tumorigenesis and disease progression in malignant brain tumors. We study how rare cancer cell populations survive and migrate in the brain, inadvertently supported by native brain cells. We develop novel cerebrospinal fluid-based biomarkers to track brain cancer treatment response, relapse, and neurotoxicity. Our bedside-to-bench-to-bedside research model builds on a foundation of generously donated patient samples, where we test mechanisms of brain cancer growth, develop novel pre-clinical models that reliably recapitulate the human disease, and facilitate clinical trials of new treatments for patients with brain cancer.
www.GephartLab.com
https://stan.md/BrainMets
@HaydenGephartMD -
Gregory M. Heestand, MD
Clinical Associate Professor, Medicine - Oncology
BioDr. Heestand is a board-certified medical oncologist with a focus on gastrointestinal cancers, primarily hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer. He serves as the medical oncology champion of the Stanford Hepatobiliary Tumor Board, as well as the principal investigator of multiple clinical trials. He collaborates with campus laboratories to help develop new biomarker and treatment technologies. He is the former director of the Stanford Oncology Fellowship Program.
Dr. Heestand and his team take great pride in helping patients and their families face gastrointestinal cancer.
Outside of the clinic, Dr. Heestand enjoys playing the piano, teaching his kids about music, cooking for friends and family, and surfing the internet for interesting things to read. -
Sarah Heilshorn
Rickey/Nielsen Professor in the School of Engineering and Professor, by courtesy, of Bioengineering and of Chemical Engineering
Current Research and Scholarly InterestsProtein engineering
Tissue engineering
Regenerative medicine
Biomaterials -
Stefan Heller, PhD, MS
Edward C. and Amy H. Sewall Professor in the School of Medicine and Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Current Research and Scholarly InterestsOur research focuses on the inner ear, from its earliest manifestation as one of the cranial placodes until it has developed into a mature and functioning organ. We are interested in how the sensory epithelia of the inner ear that harbor the sensory hair cells develop, how the cells mature, and how these epithelia respond to toxic insults. The overarching goal of this research is to find ways to regenerate lost sensory hair cells in mammals.
-
Lisa Henriksen
Associate Professor (Research) of Medicine (Stanford Prevention Research Center)
Sr Research Engineer, Medicine - Stanford Prevention Research CenterCurrent Research and Scholarly InterestsMy research aims to improve our understanding of the health risks associated with exposure to tobacco marketing and provide a scientific rationale for new policies to reduce it. I also study use of media to promote and discourage adolescent tobacco use, and the impact of tobacco advertising on urge and craving to smoke.
-
Robert Herfkens
Professor of Radiology (Cardiovascular Imaging), Emeritus
Current Research and Scholarly InterestsImaging of cardiovascular diseases with CT, magnetic resonance imaging and spectroscopy
-
Tina Hernandez-Boussard
Professor of Medicine (Biomedical Informatics), of Biomedical Data Science, of Surgery and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsMy background and expertise is in the field of computational biology, with concentration in health services research. A key focus of my research is to apply novel methods and tools to large clinical datasets for hypothesis generation, comparative effectiveness research, and the evaluation of quality healthcare delivery. My research involves managing and manipulating big data, which range from administrative claims data to electronic health records, and applying novel biostatistical techniques to innovatively assess clinical and policy related research questions at the population level. This research enables us to create formal, statistically rigid, evaluations of healthcare data using unique combinations of large datasets.
-
Rogelio A. Hernández-López
Assistant Professor of Bioengineering and of Genetics
Current Research and Scholarly InterestsOur group works at the interface of mechanistic, synthetic, and systems biology to understand and program cellular recognition, communication, and organization. We are currently interested in engineering biomedical relevant cellular behaviors for cancer immunotherapy.
-
Daniel Herschlag
Professor of Biochemistry and, by courtesy, of Chemical Engineering
Current Research and Scholarly InterestsOur research is aimed at understanding the chemical and physical behavior underlying biological macromolecules and systems, as these behaviors define the capabilities and limitations of biology. Toward this end we study folding and catalysis by RNA, as well as catalysis by protein enzymes.
-
Mark Hlatky, MD
Professor of Health Policy, of Medicine (Cardiovascular Medicine) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsMy main research work is in "outcomes research", especially examining the field of cardiovascular medicine. Particular areas of interest are the integration of economic and quality of life data into randomized clinical trials, evidence-based medicine, decision models, and cost-effectiveness analysis. I am also interested in the application of novel genetic, biomarker, and imaging tests to assess risk and guide clinical management of coronary artery disease.
-
Andrew R. Hoffman
Professor of Medicine (Endocrinology), Emeritus
Current Research and Scholarly InterestsMechanism of genomic imprinting of insulin like growth factor-2 and other genes.Long range chromatin interactions Role of histone modifications and DNA methylation in gene expression.
-
Lawrence "Rusty" Hofmann, MD
Professor of Radiology (Interventional Radiology)
BioDr. Lawrence “Rusty” Hofmann is an actively practicing physician and Professor of Interventional Radiology at Stanford School of Medicine, as well as the Chief of Industry Partnerships for Stanford Healthcare, Medical Director of Cardiac and Interventional Services, and the Medical Director of Digital Health at Stanford Medicine. He served as Chief of Interventional Radiology at Stanford for nearly two decades. He is the Co-Founder of Grand Rounds, Inc, rebranded as Included Health. He has devoted his career to providing state-of-the-art care to patients at either Johns Hopkins, where he practiced for 10 years, or Stanford, where he practiced for 15 years. He has published over 100 scientific articles on minimally invasive treatment of blood clots (DVT) and cancer. He has always had in interest in innovation. He holds 2 patents, has worked as a consultant for numerous medical device companies, both start-ups and large companies and is currently the Global-Principal Investigator for the first clinical trial testing a venous stent. He has invented and brought a number of devices from napkin stage to world-wide use. He has active digital health research projects at the intersection of artificial intelligence and clinical care, including telemedicine and deep venous thrombosis.
-
Chris Holsinger, MD, FACS
Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Master of Liberal Arts Student, admitted Autumn 2024Current Research and Scholarly InterestsDr. Holsinger’s surgical practice focuses on the surgical management of benign and malignant diseases of the thyroid, parathyroid and head and neck.
His areas of clinical interest include endoscopic head and neck surgery, including robotic thyroidectomy, transoral robotic surgery and transoral laser microsurgery, as well as time-honoured approaches of conservation laryngeal surgery, supracricoid partial laryngectomy.
